Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PAIN.V
Strong SellVector Science and Therapeutics Corp. · Healthcare · United States · $244M · Avg Vol: $395K/d
9
StockRankGet insider-trade alerts
Q
33
V
21
M
25
P/E (TTM)
—
ROE
-104.1%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Vector Science and Therapeutics Corp. develops and sells novel biomechanical devices and active localized drug-delivery platforms. The company offers products and services based on its Smart, Steered, and Sustained framework for site-directed interventions in musculoskeletal tissue regeneration.
FINANCIAL SUMMARY (CAD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | — | 0 | — |
| EPS (CAD) | — | -0.01 | -0.02 |
| Shares | 153.3M | 153.3M | 156.4M |
| Debt | — | — | — |
| Equity | 832 | 2.4M | — |
| Op CF | — | -1.1M | -1.1M |
| Inv CF | — | -32.6K | — |
| Fin CF | — | 5.1M | — |
Loading 1Y...
PRICE (1Y)+32.7%
SMA 50SMA 200
Close
$1.55
RSI (14)
65.1
SCORE BREAKDOWN
Quality
33
ROIC
-29.9%25.8
ROE
-104.1%9.8
GP/Assets
-5.0%7.6
Op. Margin
0.0%40.0
FCF/Assets
-26.5%16.7
Piotroski
239.8
Int. Cover
-1.7x33.7
D/E Ratio
0.00x97.9
Current Ratio
11.81x89.3
Value
21
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
85.0x1.1
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$244M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PAIN.V are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PAIN.V | Vector Science and Therapeutics Corp.(you) | $244M | 9 | Strong Sell |
| LUCD | Lucid Diagnostics Inc. | $189M | 7 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 12 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| QSI | Quantum-Si incorporated | $171M | 13 | Strong Sell |
| CATX | Perspective Therapeutics, Inc. | $355M | 14 | Strong Sell |
| EBR.AX | EBR Systems, Inc. | $148M | 6 | Strong Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| OWLT | Owlet, Inc. | $146M | 14 | Strong Sell |
| IMR.AX | Imricor Medical Systems, Inc. | $506M | 8 | Strong Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%